Investigation of rate + extent of excretion of radioactivity in urine +faeces after oral administration of [14C]AZD2066
Study identifier:D0475C00008
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
Study Complete
Official Title
An Open label, Single dose, Phase I study of the Excretion of Radioactivity, Metabolism and Pharmacokinetics following Oral administration of [14C]AZD2066 to Healthy Male Subjects
Medical condition
Pain
Phase
Phase 1
Healthy volunteers
Yes
Study drug
AZD2066
Sex
Male
Actual Enrollment
6
Study type
Interventional
Age
35 Years - 50 Years
Date
Study Start Date: 01 Jan 2009
Primary Completion Date: -
Study Completion Date: 01 Feb 2009
Study design
Allocation: N/A
Endpoint Classification: Pharmacokinetics Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Other
Verification:
Verified 01 Nov 2013 by AstraZeneca Pharmaceuticals
Sponsors
AstraZeneca Pharmaceuticals
Collaborators
-
Inclusion and exclusion criteria
Loading...
No locations available
| Arms | Assigned Interventions |
|---|
Contacts
Investigators
Principal Investigator
Emeline Ramos
AstraZeneca R&D, CPU Alderley Park, UK
